JPMorgan: Maintain Alibaba Health (00241) "overweight" rating with a target price of HK $10.7

智通财经2020-02-10

Zhitong Finance APP learned that JPMorgan released a report saying that Alibaba Health (00241) recently announced the acquisition of the Tmall drug sales platform from its parent company Alibaba (09988). RMB, the total transaction consideration is 8.075 billion yuan, equivalent to approximately 0.76 times the valuation/total transaction volume of the platform. The bank added that it has a positive sense of the above-mentioned transactions, and said that the timing of injecting the drug business is good, which will help Alibaba Health develop an online prescription drug sales platform in the mainland and further strengthen Alibaba Health's position as the flagship platform of Alibaba's big health. It believes...

Web link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment